Abstract

Periodontal disease is an age-associated disorder clinically defined by periodontal bone loss, inflammation of the specialized tissues that surround and support the tooth, and microbiome dysbiosis. Currently, there is no therapy for reversing periodontal disease, and treatment is generally restricted to preventive measures or tooth extraction. The FDA-approved drug rapamycin slows aging and extends lifespan in multiple organisms, including mice. Here we demonstrate that short-term treatment with rapamycin rejuvenates the aged oral cavity of elderly mice, including regeneration of periodontal bone, attenuation of gingival and periodontal bone inflammation, and revertive shift of the oral microbiome toward a more youthful composition. This provides a geroscience strategy to potentially rejuvenate oral health and reverse periodontal disease in the elderly.

Data availability

The V4-16S rDNA sequences in raw format, prior to post-processing and data analysis, have been deposited at the European Nucleotide Archive (ENA) under study accession no. PRJEB35672.Dryad Data link: http://dx.doi.org/10.5061/dryad.f4qrfj6sn

The following data sets were generated

Article and author information

Author details

  1. Jonathan Y An

    Oral Health Sciences and Pathology, University of Washington, Seattle, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8422-8608
  2. Kristopher A Kerns

    University of Washington, Washington, United States
    Competing interests
    No competing interests declared.
  3. Andrew Ouellette

    The Jackson Laboratory, Bar Harbor, United States
    Competing interests
    No competing interests declared.
  4. Laura Robinson

    The Jackson Laboratory, Bar Harbor, United States
    Competing interests
    No competing interests declared.
  5. H Douglas Morris

    The Jackson Laboratory, Bar Harbor, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7942-3748
  6. Catherine Kaczorowski

    The Jackson Laboratory, Bar Harbor, United States
    Competing interests
    No competing interests declared.
  7. So-Il Park

    Oral Health Sciences and Pathology, University of Washington, Seattle, United States
    Competing interests
    No competing interests declared.
  8. Title Mekvanich

    Oral Health Sciences and Pathology, University of Washington, Seattle, United States
    Competing interests
    No competing interests declared.
  9. Alex Kang

    Oral Health Sciences and Pathology, University of Washington, Seattle, United States
    Competing interests
    No competing interests declared.
  10. Jeffrey S McLean

    Department of Periodontics and Oral Health Sciences Adjunct Department of Microbiology, University of Washington, Seattle, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9934-5137
  11. Timothy C Cox

    University of Missouri-Kansas City, Kansas City, United States
    Competing interests
    No competing interests declared.
  12. Matt Kaeberlein

    Department of Pathology, University of Washington, Seattle, United States
    For correspondence
    kaeber@uw.edu
    Competing interests
    Matt Kaeberlein, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1311-3421

Funding

National Institute of Dental and Craniofacial Research (DE027254,DE023810,DE020102)

  • Jonathan Y An
  • Jeffrey S McLean

National Institute on Aging (AG054180,AG038070,AG038070)

  • Catherine Kaczorowski

National Institutes of Health (TR002318)

  • Kristopher A Kerns

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the University of Washington (#4359-01) and of the Jackson Laboratory (#06005-A24) .

Copyright

© 2020, An et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 7,657
    views
  • 842
    downloads
  • 65
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jonathan Y An
  2. Kristopher A Kerns
  3. Andrew Ouellette
  4. Laura Robinson
  5. H Douglas Morris
  6. Catherine Kaczorowski
  7. So-Il Park
  8. Title Mekvanich
  9. Alex Kang
  10. Jeffrey S McLean
  11. Timothy C Cox
  12. Matt Kaeberlein
(2020)
Rapamycin rejuvenates oral health in aging mice
eLife 9:e54318.
https://doi.org/10.7554/eLife.54318

Share this article

https://doi.org/10.7554/eLife.54318

Further reading

    1. Cell Biology
    Yajun Zhai, Peiyi Liu ... Gongzheng Hu
    Research Article

    Discovering new strategies to combat the multidrug-resistant bacteria constitutes a major medical challenge of our time. Previously, artesunate (AS) has been reported to exert antibacterial enhancement activity in combination with β-lactam antibiotics via inhibition of the efflux pump AcrB. However, combination of AS and colistin (COL) revealed a weak synergistic effect against a limited number of strains, and few studies have further explored its possible mechanism of synergistic action. In this article, we found that AS and EDTA could strikingly enhance the antibacterial effects of COL against mcr-1- and mcr-1+ Salmonella strains either in vitro or in vivo, when used in triple combination. The excellent bacteriostatic effect was primarily related to the increased cell membrane damage, accumulation of toxic compounds and inhibition of MCR-1. The potential binding sites of AS to MCR-1 (THR283, SER284, and TYR287) were critical for its inhibition of MCR-1 activity. Additionally, we also demonstrated that the CheA of chemosensory system and virulence-related protein SpvD were critical for the bacteriostatic synergistic effects of the triple combination. Selectively targeting CheA, SpvD, or MCR using the natural compound AS could be further investigated as an attractive strategy for the treatment of Salmonella infection. Collectively, our work opens new avenues toward the potentiation of COL and reveals an alternative drug combination strategy to overcome COL-resistant bacterial infections.

    1. Cell Biology
    Tamás Visnovitz, Dorina Lenzinger ... Edit I Buzas
    Short Report

    Recent studies showed an unexpected complexity of extracellular vesicle (EV) biogenesis pathways. We previously found evidence that human colorectal cancer cells in vivo release large multivesicular body-like structures en bloc. Here, we tested whether this large EV type is unique to colorectal cancer cells. We found that all cell types we studied (including different cell lines and cells in their original tissue environment) released multivesicular large EVs (MV-lEVs). We also demonstrated that upon spontaneous rupture of the limiting membrane of the MV-lEVs, their intraluminal vesicles (ILVs) escaped to the extracellular environment by a ‘torn bag mechanism’. We proved that the MV-lEVs were released by ectocytosis of amphisomes (hence, we termed them amphiectosomes). Both ILVs of amphiectosomes and small EVs separated from conditioned media were either exclusively CD63 or LC3B positive. According to our model, upon fusion of multivesicular bodies with autophagosomes, fragments of the autophagosomal inner membrane curl up to form LC3B positive ILVs of amphisomes, while CD63 positive small EVs are of multivesicular body origin. Our data suggest a novel common release mechanism for small EVs, distinct from the exocytosis of multivesicular bodies or amphisomes, as well as the small ectosome release pathway.